Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

7.330 +0.190 (+2.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,761,628
Open 7.170
Bid (Size) 7.400 (2)
Ask (Size) 7.610 (5)
Prev. Close 7.140
Today's Range 7.060 - 7.460
52wk Range 6.330 - 14.23
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
The better of the pair should be able to beat Bluebird Bio. 
Via The Motley Fool
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga

Performance

YTD
-13.15%
-13.15%
1 Month
-16.99%
-16.99%
3 Month
-11.47%
-11.47%
6 Month
+5.16%
+5.16%
1 Year
-40.55%
-40.55%

More News

Read More
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
Via Benzinga
Expert Ratings for Editas Medicine
Via Benzinga
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 9/29
Via Investor Brand Network
Analyst Expectations for Editas Medicine's Future
Via Benzinga
Expert Ratings for Editas Medicine
Via Benzinga
Why Editas Medicine Stock Is Soaring Today
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
Via Benzinga
Nike To Rally Around 53%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Is Editas Medicine Stock a Buy Now?
Via The Motley Fool
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Gene Editing Stock to Buy Now, and 1 to Sell
Via The Motley Fool
Editas Medicine Announces Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
Via The Motley Fool
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
From Editas Medicine, Inc.
Via GlobeNewswire
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.